183 related articles for article (PubMed ID: 34277801)
1. Apatinib enhances the anti-tumor effect of paclitaxel via the PI3K/p65/Bcl-xl pathway in triple-negative breast cancer.
Chen J; Deng S; Zhang Y; Wang C; Hu X; Kong D; Liang G; Yuan X; Li Y; Wang X
Ann Transl Med; 2021 Jun; 9(12):1001. PubMed ID: 34277801
[TBL] [Abstract][Full Text] [Related]
2. The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer.
Li J; Zhang D; Liu Z; Wang Y; Li X; Wang Z; Liang G; Yuan X; Li Y; Komorowski AL; Rozen WM; Orlandi A; Takabe K; Franceschini G; Jerusalem G; Wang X
Ann Transl Med; 2023 Jan; 11(2):83. PubMed ID: 36819490
[TBL] [Abstract][Full Text] [Related]
3. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
Gao Z; Shi M; Wang Y; Chen J; Ou Y
Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel inhibits proliferation and invasion and promotes apoptosis of breast cancer cells by blocking activation of the PI3K/AKT signaling pathway.
Li G; Xu D; Sun J; Zhao S; Zheng D
Adv Clin Exp Med; 2020 Nov; 29(11):1337-1345. PubMed ID: 33269821
[TBL] [Abstract][Full Text] [Related]
5. Apatinib weakens resistance of gastric cancer cells to paclitaxel by suppressing JAK/STAT3 signaling pathway.
Bei Y; Chen X; Xu Q; Lv J; Hu J; Yang S
Drug Dev Res; 2022 Apr; 83(2):379-388. PubMed ID: 34405891
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
7. Synergistic anticancer mechanisms of curcumol and paclitaxel in triple-negative breast cancer treatment may involve down-regulating ZBTB7A expression via the NF-B signaling pathway.
Mao A; Qin Q; Yang W; Wei C
Iran J Basic Med Sci; 2022 May; 25(5):652-658. PubMed ID: 35911648
[TBL] [Abstract][Full Text] [Related]
8. Apatinib suppresses the Proliferation and Apoptosis of Gastric Cancer Cells via the PI3K/Akt Signaling Pathway.
Jia X; Wen Z; Sun Q; Zhao X; Yang H; Shi X; Xin T
J BUON; 2019; 24(5):1985-1991. PubMed ID: 31786865
[TBL] [Abstract][Full Text] [Related]
9. Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-κB and ERK pathways.
Wang P; Song D; Wan D; Li L; Mei W; Li X; Han L; Zhu X; Yang L; Cai Y; Zhang R
PeerJ; 2020; 8():e9281. PubMed ID: 32547883
[TBL] [Abstract][Full Text] [Related]
10. MiR-153-5p Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Paclitaxel by Inducing G2M Phase Arrest.
Wang Y; Wu N; Zhang J; Wang H; Men X
Onco Targets Ther; 2020; 13():4089-4097. PubMed ID: 32494162
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling.
Zhang J; Xu HX; Wu YL; Cho WCS; Xian YF; Lin ZX
Adv Biol (Weinh); 2023 Aug; 7(8):e2300062. PubMed ID: 37401656
[TBL] [Abstract][Full Text] [Related]
12. Apatinib Reverses Paclitaxel-resistant Lung Cancer Cells (A549) Through Blocking the Function of ABCB1 Transporter.
Zhang Q; Song Y; Cheng X; Xu Z; Matthew OA; Wang J; Sun Z; Zhang X
Anticancer Res; 2019 Oct; 39(10):5461-5471. PubMed ID: 31570440
[TBL] [Abstract][Full Text] [Related]
13. Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1.
Liu H; Wang Y; Li X; Zhang YJ; Li J; Zheng YQ; Liu M; Song X; Li XR
Tumour Biol; 2013 Jun; 34(3):1713-22. PubMed ID: 23430586
[TBL] [Abstract][Full Text] [Related]
14. Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody.
Liu J; Wang P; Huang B; Cheng Q; Duan Y; Chen L; Ma T; Zhu C; Li D; Fan W; Yu M
Int J Pharm; 2022 Aug; 624():121969. PubMed ID: 35803533
[TBL] [Abstract][Full Text] [Related]
15. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
Haynes BM; Cunningham K; Shekhar MPV
BMC Cancer; 2022 Oct; 22(1):1073. PubMed ID: 36258187
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of p300 in paclitaxel-resistant TNBC: implications for cell proliferation via the PCK1/AMPK axis.
Zhao PW; Cui JX; Wang XM
Pharmacogenomics J; 2024 Feb; 24(2):5. PubMed ID: 38378770
[TBL] [Abstract][Full Text] [Related]
17. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
Yuan Z; Jiang H; Zhu X; Liu X; Li J
Biomed Pharmacother; 2017 May; 89():227-232. PubMed ID: 28231544
[TBL] [Abstract][Full Text] [Related]
18. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell.
Huang M; Huang B; Li G; Zeng S
BMC Gastroenterol; 2018 Nov; 18(1):169. PubMed ID: 30400838
[TBL] [Abstract][Full Text] [Related]
19. [The inhibition effects of apatinib on cell proliferation, migration and apoptosis in esophageal carcinoma via Ras/Raf/MEK/ERK and JAK2/STAT3 pathways].
Feng Y; Zhou MY; Sun F; Kong Z; Wang J; Sun ZQ; Hu LJ; Wang JL; Hua Q; Yu JP
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):263-275. PubMed ID: 31014051
[No Abstract] [Full Text] [Related]
20. Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway.
Zhang W; Cai J; Chen S; Zheng X; Hu S; Dong W; Lu J; Xing J; Dong Y
Mol Med Rep; 2015 Jul; 12(1):1506-14. PubMed ID: 25760096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
